More Articles
The Somatomedin and Dual Effector Theories of Growth Hormone Action Submitted by Alan D. Rogol, M.D., Ph.D. The somatomedin hypothesis stated that the uptake of sulfate in, for example rat…
New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved by the FDA in…
Historical Tidbit: Robert T. Morris (1857-1945) and Human Ovarian Transplantation Submitted by Alan D. Rogol, M.D., Ph.D. Robert Morris was an exceptional surgeon in New York City. He was among…
Patricia Chu, MD I am a fourth-year Combined Adult and Pediatric Endocrinology Fellow at Penn Medicine/Children’s Hospital of Philadelphia and am currently in the Master of Science in Clinical Epidemiology (MSCE)…
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) were approved by the…
New Meds and Tech from PES Drugs and Therapeutics committee Palovarotene (SohonosTM – Ipsen Pharmaceuticals Inc.) By: Ambika Ashraf, MD and Anna Ryabets-Lienhard, DO Update: 9/10/2023 On August…
Historical Tidbit: Paracelsus (1493-1541). A Man for All Seasons Submitted by Alan D. Rogol, M.D., Ph.D. Paracelsus, born Philippus Aureolus Theophrastue Bombastus von Hoenheim was a Swiss chemist and physician…
Ana Menendez, MD My name is Ana Menendez and I am a third-year pediatric endocrinology fellow at the University of Connecticut, Connecticut Children’s Medical Center. I obtained my medical degree…
